A committee of Japan's health ministry has approved US biotechnology company Novavax Inc's (Nasdaq:NVAX) COVID-19 vaccine, Reuters news agency reported on Monday.
If granted full approval, this will be Japan's fourth COVID-19 vaccine.
The Japanese government has reportedly agreed to purchase 150 million doses of Novavax's recombinant protein type vaccine, which will be manufactured in Japan by Takeda Pharmaceutical Co (Tokyo:4502).
So far, most of Japan's COVID-19 vaccinations have been carried out with the mRNA vaccines made by US pharmaceutical companies Pfizer Inc (NYSE:PFE) and Moderna Inc (Nasdaq:MRNA).
The vaccine from British pharmaceutical company Astrazeneca plc (LON:AZN) has also been approved, but most domestically produced supplies have not been used in Japan and instead donated overseas.
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
Avance Biosciences registers with CLIA program
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine